KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) EBITDA (2016 - 2025)

Pacira BioSciences has reported EBITDA over the past 16 years, most recently at $2.3 million for Q4 2025.

  • Quarterly results put EBITDA at $2.3 million for Q4 2025, down 90.53% from a year ago — trailing twelve months through Dec 2025 was $19.2 million (up 126.16% YoY), and the annual figure for FY2025 was $19.2 million, up 126.16%.
  • EBITDA for Q4 2025 was $2.3 million at Pacira BioSciences, down from $6.4 million in the prior quarter.
  • Over the last five years, EBITDA for PCRX hit a ceiling of $39.9 million in Q2 2023 and a floor of -$139.5 million in Q3 2024.
  • Median EBITDA over the past 5 years was $17.6 million (2022), compared with a mean of $9.2 million.
  • Biggest five-year swings in EBITDA: soared 587.52% in 2021 and later tumbled 887.35% in 2024.
  • Pacira BioSciences' EBITDA stood at $4.2 million in 2021, then plummeted by 334.93% to -$9.9 million in 2022, then soared by 435.27% to $33.2 million in 2023, then dropped by 25.52% to $24.7 million in 2024, then crashed by 90.53% to $2.3 million in 2025.
  • The last three reported values for EBITDA were $2.3 million (Q4 2025), $6.4 million (Q3 2025), and $8.5 million (Q2 2025) per Business Quant data.